How an unsolved medical mystery became a life-saving breakthrough

Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...
InsideNoVa

Breathing Easier: A Minimally Invasive Option for Severe COPD/Emphysema

(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...

Doctors Recommend These Remedies to Get Rid of Phlegm

The best ways to get rid of phlegm, from using nasal sprays to taking the right OTC medications. Plus, they explain what ...
Healio

Cost-related nonadherence linked to negative COPD outcomes

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...